Anti-tumour necrosis factor treatment for the prevention of ischaemic events in patients with deficiency of adenosine deaminase 2 (DADA2).
暂无分享,去创建一个
S. Cooray | K. Armon | R. Goel | C. Papadopoulou | S. Jolles | S. Dubey | L. Harper | S. Berg | D. Eleftheriou | P. Brogan | M. Wood | E. Al-Abadi | Ying Hong | M. Ekelund | Ebun Omyinmi